Inmed Pharmaceuticals Inc. has released new preclinical data on INM-089 further demonstrating promising pharmacological effects targeting dry age-related macular degeneration (AMD). INM-089 is a proprietary small-molecule compound acting as a preferential signaling ligand of cannabinoid CB1 and CB2 receptors.